A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women

BACKGROUND AND OBJECTIVE: Relugolix is a gonadotropin-releasing hormone receptor antagonist. Relugolix 40-mg monotherapy is associated with vasomotor symptoms and long-term bone mineral density loss due to hypoestrogenism. This study assessed whether the addition of estradiol (E2) 1 mg and norethind...

Descripción completa

Detalles Bibliográficos
Autores principales: Lukes, Andrea, Migoya, Elizabeth, Johnson, Brendan, Lee, Tien-Yi, Li, Yulan, Arjona Ferreira, Juan Camilo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386916/
https://www.ncbi.nlm.nih.gov/pubmed/37365436
http://dx.doi.org/10.1007/s40262-023-01269-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386916/
https://www.ncbi.nlm.nih.gov/pubmed/37365436
http://dx.doi.org/10.1007/s40262-023-01269-9

Ejemplares similares